Stable-form screening: overcoming trace impurities that inhibit solution-mediated phase transformation to the stable polymorph of sulfamerazine.

Solution-mediated phase transformation (SMPT) has been used as a focused technique to rapidly identify the stable polymorph of a given substance. Despite ample precedence for acetonitrile being a good solvent for SMPT of sulfamerazine (SMZ), samples from specific lots of SMZ failed to convert from Form I to Form II after suspension for 2 weeks in acetonitrile. In these lots, an acetyl derivative of SMZ was identified and shown to impede transformation to the stable polymorph. The inhibitory effect of this impurity on polymorphic conversion was overcome with practical adjustments to experimental procedure, which hastened the kinetics of SMPT. The critical factors considered were (1) modifying the solvent to increase solubility, (2) minimizing the level of impurity in the slurries, (3) pre-treatment of the solid to quickly reach maximum supersaturation, and (4) temperatures that optimized kinetics as well as the free energy difference between enantiotropically related polymorphs.

[1]  W. Ostwald.  Studien über die Bildung und Umwandlung fester Körper , 1897 .

[2]  R. Roblin,et al.  Chemotherapy. II. Some Sulfanilamido Heterocycles1 , 1940 .

[3]  H. Brittain.  Polymorphism in Pharmaceutical Solids , 1999 .

[4]  D. Grant,et al.  Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. , 2001, Journal of pharmaceutical sciences.

[5]  R. Roblin,et al.  Chemotherapy. I. Substituted Sulfanilamidopyridines1 , 1940 .

[6]  D. Grant.  THEORY AND ORIGIN OF POLYMORPHISM , 1999 .

[7]  J. Guillory,et al.  Polymorphism in sulfonamides. , 1972, Journal of pharmaceutical sciences.

[8]  R. Davey,et al.  The kinetics of solvent-mediated phase transformations , 1985, Proceedings of the Royal Society of London. A. Mathematical and Physical Sciences.

[9]  N. Rodríguez-Hornedo,et al.  Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. , 1999, Journal of pharmaceutical sciences.

[10]  M. Caria,et al.  Positive indentification of two orthorhombic polymorphs of sulfamerazine (C11H12N4O2S), their thermal analyses and structural comparison , 1992 .

[11]  David J W Grant,et al.  Identifying the Stable Polymorph Early in the Drug Discovery–Development Process , 2005, Pharmaceutical development and technology.

[12]  G. Kartha,et al.  Crystal structure of sulfamerazine , 1982 .

[13]  Alfons Mersmann,et al.  Calculation of interfacial tensions , 1990 .

[14]  David J.W. Grant,et al.  Stabilization of a metastable polymorph of sulfamerazine by structurally related additives , 2002 .

[15]  Joel Bernstein,et al.  Polymorphism in Molecular Crystals , 2002 .